Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Immune begins Phase I/II of Ceplene in CMML

July 14, 2017 8:32 PM UTC

Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) began a Phase I/II trial to evaluate twice-daily 0.5 mg subcutaneous Ceplene histamine dihydrochloride plus low-dose IL-2 in 15 patients with chronic myelomonocytic leukemia (CMML).

Patients will receive Ceplene with or without IL-2 for 3 consecutive weeks of a 6-week cycle for 4 cycles, after which patients can continue treatment for 3 consecutive weeks of a 9-week cycle for 6 additional cycles...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Immune Pharmaceuticals Inc.